Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria
- 1 May 2005
- Vol. 23 (24), 3131-3138
- https://doi.org/10.1016/j.vaccine.2004.12.019
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- BLOCKING OF TRANSMISSION TO MOSQUITOES BY ANTIBODY TO PLASMODIUM VIVAX MALARIA VACCINE CANDIDATES PVS25 AND PVS28 DESPITE ANTIGENIC POLYMORPHISM IN FIELD ISOLATESThe American Journal of Tropical Medicine and Hygiene, 2003
- Expression of malaria transmission-blocking vaccine antigen Pfs25 in Pichia pastoris for use in human clinical trialsVaccine, 2002
- Large-Scale Purification and Characterization of Malaria Vaccine Candidate Antigen Pvs25H for Use in Clinical TrialsProtein Expression and Purification, 2002
- Progress and challenges for malaria vaccinesNature, 2002
- Interaction between Host Complement and Mosquito-Midgut-StagePlasmodium bergheiInfection and Immunity, 2001
- Current developments in malaria transmission-blocking vaccinesExpert Opinion on Biological Therapy, 2001
- Transmission blocking malaria vaccinesVaccine, 2001
- The neglected burden of Plasmodium vivax malariaThe American Journal of Tropical Medicine and Hygiene, 2001
- Antibodies to Malaria Vaccine Candidates Pvs25 and Pvs28 Completely Block the Ability ofPlasmodium vivaxTo Infect MosquitoesInfection and Immunity, 2000
- Biosynthesis of the 25-kDa protein in the macrogametes/zygotes of Plasmodium falciparumExperimental Parasitology, 1990